NRG G0281

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian



A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer


G0281 has met its target accrual goal in the U.S. and the study is no longer accepting any additional specimens for screening.  Closure notice to follow soon.